anadolu klin Anatolian Clinic the Journal of Medical Sciences 2149-5254 2458-8849 Hayat Sağlık ve Sosyal Hizmetler Vakfı 10.21673/anadoluklin.284462 Health Care Administration Sağlık Kurumları Yönetimi Physiopathological Treatment Approach and Position of Pioglitazone in Type 2 Diabetes Tip 2 Diyabette Fizyopatolojik Tedavi Yaklaşımı ve Pioglitazonun Yeri Şenyiğit Abdulhalim MALTEPE ÜNİVERSİTESİ Kanat Mustafa Bursa Şevket Yılmaz Eğitim Araştırma Hastanesi 09 25 2017 22 3 220 223 04 01 2017 06 15 2017 Copyright © 1933, Anadolu Kliniği Tıp Bilimleri Dergisi 1933 Anadolu Kliniği Tıp Bilimleri Dergisi

The glisemic controls are inadequate for over %50 of diabetic patients, despite modern treatment approaches in diabetes. Factors related with patient, physician and health system and also progressive character of the illness can be discussed in the issue that glisemic controls cannot be achieved adequately. The main principles of type 2 diabetes treatment and the position of pioglitazone as an insulinsensitizer were investigated in this revision.

Moderndiyabet tedavi yaklaşımlarına rağmen diyabetik hastaların %50’den fazlasındaglisemik kontroller yetersizdir. Glisemik kontrollerinin yeterincegerçekleştirilememesinde hasta, hekim ve sağlık sistemini ilgilendirenfaktörler söz konusu olmakla beraber hastalığın progresif bir karakterde olmasının da önemli etkisi sözkonusudur. Bu derlemede tip 2 diyabet tedavisinin ana ilkeleri ve insulin duyarlılaştırıcıolarak pioglitazonun yeri gözden geçirilmiştir

 Type 2 diabetes (T2DM) pioglitazone Diyabet mellitus Pioglitazon İnsülin Direnci 1. Defronzo RA: Banting Lecture. From the Triumvirate to the Ominous Octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–795. 2. Defronzo RA, et al. Pathophysiologic Approach to Therapy in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Care 2013; 26 (Supplement 2): S127-S138. 3. DeFronzo RA: Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270–1287. 4. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–1118. 5. Eldor R. et al. In Vivo Actions of Peroxisome Proliferator-Activated Receptors. Diabetes Care 2013; 26 (Supplement 2): S162-S174. 6. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572–2581 105. 7. Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561– 1573 106. 8. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–1289. 9. Kernan W.N. et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016; 374: 1321-1331. 10. G. et al. Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes. Diabetes Care 2013; 26 (Supplement 2): S155-S161. 11. Standard of Medical Care in Diabetes 2017. Diabetes Care 2017; 40 (supplement 1): 64-74.